ebronucimab   Click here for help

GtoPdb Ligand ID: 13786

Synonyms: AK-102 | AK102 | inusimab
Approved drug
ebronucimab is an approved drug
Compound class: Antibody
Comment: Ebronucimab (AK-102) is a subcutaneous fully human anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. It blocks binding between circulating PCSK9 and the LDL receptor on hepatocytes. This reduces LDL receptor degradation, thus increasing the number of LDL receptors on cells, and effectively increasing hepatic removal LDL cholesterol from the circulation. Ebronucimab was developed for patients at high risk for cardiovascular disease when lipid-lowering cannot be achieved with statins or statins + ezetimibe.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2024)
International Nonproprietary Names Click here for help
INN number INN
11476 ebronucimab
Synonyms Click here for help
AK-102 | AK102 | inusimab
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1089
Other databases
GtoPdb PubChem SID 507750419
Search PubMed clinical trials ebronucimab
Search PubMed titles ebronucimab
Search PubMed titles/abstracts ebronucimab